IT-101: Clinical Trials

6 trials of IT-101, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated, 2 completed. 6 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Terminated 4, Completed 2
Phase 24Terminated 3, Completed 1

Follow IT-101: new trials by email Literature Review of IT-101 trials Research Report on IT-101

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)452016-05-092026-08-13
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
CRLX101, Bevacizumab, mFOLFOX6 - Solid Tumors
Phase 1TerminatedNewLink Genetics Corporation412015-10-012020-05-28
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
CRLX101, Paclitaxel - Ovarian Cancer
Phase 1 / Phase 2TerminatedNewLink Genetics Corporation302015-07-012026-06-18
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
CRLX101, Capecitabine, Radiotherapy - Rectal Cancer
Phase 1 / Phase 2TerminatedUNC Lineberger Comprehensive Cancer Center322013-12-012020-11-03
CRLX101 Plus Bevacizumab in Advanced RCC
CRLX101 (Cerulean), Bevacizumab - Renal Cell Carcinoma
Phase 1CompletedAbramson Cancer Center at Penn Medicine222012-06-012018-08-29
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer - Cancer, Solid Tumor
Phase 1 / Phase 2CompletedNewLink Genetics Corporation622006-05-012020-05-28

Conditions studied

Lung Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Rectal Neoplasms (1)

Sponsors

NewLink Genetics Corporation (3)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  National Cancer Institute (NCI) (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)

Countries

United States (6)

Top investigators

Andrew Wang, MD (1)  ·  Anish Thomas, M.D. (1)  ·  Glenn Weiss, M.D. (1)  ·  Jeffrey D. Neidhart, M.D. (1)  ·  Naomi M Haas, MD (1)  ·  NewLink Ge (1)  ·  Yun Yen, M.D., Ph.D. (1)

Results publications

PMID 27784746, PMID 30858085, PMID 32897402, PMID 33390325, PMID 42820295